Celsius Therapeutics Appoints Sarah Grant, M.D., as Chief Medical Officer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and autoimmune disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced the appointment of Sarah Grant, M.D., as chief medical officer. In this role, Dr. Grant will lead the company’s clinical strategy and development of its pipeline of therapies for autoimmune disease and cancer, including its potential first-in-class TREM1 antibody program for inflammatory bowel disease.

“I am delighted to welcome Sarah as our first chief medical officer,” said Tariq Kassum, M.D., president and CEO of Celsius. “Sarah brings deep translational and clinical medicine expertise to Celsius, with more than two decades of experience working across multiple therapeutic areas and all stages of drug development, which will be instrumental as Celsius transitions into a clinical-stage company. We look forward to her important contributions in advancing our pipeline of precision medicines in autoimmune disease and cancer.”

Dr. Grant is an accomplished physician-scientist who brings to Celsius more than 20 years of experience in translational medicine, early and late-stage drug development, and clinical medicine. Prior to Celsius, Dr. Grant spent nine years at Novartis in multiple senior leadership roles, most recently as the chief of staff and strategic assistant for the head of global drug development. Previously at Novartis, she was head of respiratory discovery within translational medicine. She began her career at Novartis leading multiple early-stage clinical programs focused in pulmonary and immunology indications. Prior to Novartis, Dr. Grant was on the faculty at Harvard Medical School and was an attending physician at the Brigham and Women’s Hospital. Dr. Grant completed her internship and residency at the Brigham and Women’s Hospital. She holds an M.D. from Stanford University School of Medicine and an A.B. from Harvard University.

“Through deep analysis of proprietary and meticulously curated datasets from human tissue samples, Celsius has pioneered a new path to understand the cells that drive disease progression for heterogeneous diseases with complex disease biology,” said Dr. Grant. “This approach unlocks novel insights into targets and patient subsets, with the potential to deliver the right therapeutics to the right patients. I am so excited to join Celsius at this important time as the company translates these novel insights into its first clinical programs.”

About Celsius Therapeutics

Celsius Therapeutics is a biotechnology company developing novel precision medicines in autoimmune disease and cancer by harnessing the power of single cell RNA sequencing and human biology at scale. The company’s first therapeutic candidate is an anti-TREM1 antibody for the treatment of inflammatory bowel disease, and the company has multiple ongoing drug discovery programs in oncology. Celsius is based in Cambridge, Mass. For more information, please visit www.celsiustx.com, or follow us on LinkedIn or Twitter.

Contacts

Katie Engleman, 1AB

[email protected]